預計到 2028 年全球生物相似藥市場的成長機會

提高獲取、採用和認知度是生物相似藥未來成長潛力的關鍵

在生物相似藥製造商和法規機構的主導，隨著患者和醫療保健專業人員對治療的理解和認知不斷提高，生物相似藥的接受度和使用量正在增加。隨著越來越多的資訊和實用資料可得性生物相似藥的安全性和有效性，患者和醫療保健專業人員對它們的信心不斷增強。製藥公司必須巧妙地平衡保護自家公司生物製藥和培育有利於生物相似藥存在的環境之間的複雜平衡，這不可避免地有助於繁榮的競爭環境。

本研究介紹了全球生物相似藥市場的整體狀況以及按細分市場分類的收益預測。我們根據生物相似藥市場參與企業的趨勢、不斷發展的商業模式以及各相關人員的策略必要事項來強調關鍵的成長機會。確定產生最多收益的治療領域和產品類型。強調影響區域生物相似藥採用和生物相似藥市場進入的因素。此外，本報告還討論了可能影響生物相似藥滲透率的複雜要素，包括報銷和付款人情況、生物相似藥價格趨勢和生物相似藥銷售趨勢。該研究還討論了行業問題，例如區域生物學名藥差異、醫生招聘和專利訴訟。該報告確定了加速生物相似藥普及和創新以及在神經病學和腫瘤學等新治療領域競爭的關鍵成長機會。

目錄

戰略問題

• 成長為何困難
• The Strategic Imperative 8（TM）
• 戰略要務對全球生物相似藥市場的影響
• 成長機會是Growth Pipeline Engine（TM）

成長機會分析

• 分析範圍
• 市場區隔
• 生物相似藥市場的主要區域競爭
• 成長促進因素
• 成長抑制因素

生物相似藥市場的成長環境

• 亮點 - 生物相似藥的區域動態
• 成長機會 - 生物相似藥市場
• 促進生物相似藥開發和普及的策略
• 生物相似藥-山德士主導生物相似藥的普及
• 北美競爭基準化分析- 主要國家
• 市場概述—美國生物相似藥市場
• 生物相似藥在美國核准
• 美國醫療保健金融和配銷通路
• 利用下一波生物相似藥改變商業模式
• PBM 配方在提高生物相似藥可及性方面的作用不斷演變
• 不斷變化的美國生物相似藥法規環境
• 由於 IRA 反應，美國胰島素生物相似藥市場經歷重大調整
• 美國的雙重定價策略
• 美國癌症領域
• 美國癌症支持護理
• 美國免疫學/眼科
• 歐洲競爭基準化分析- 主要國家
• 市場概述– 歐洲生物相似藥市場
• 生物相似藥在歐洲核准
• 快速推出生物相似藥—丹麥的成功故事
• 促進生物相似藥採用的激勵措施
• 亞太和中東/非洲競爭基準化分析- 主要國家
• 市場概述- 亞太地區、中東和非洲的主要生物相似藥市場
• 亞洲生物製藥和 CDMO 的全球市場日益受到關注

成長機會分析 - 生物相似藥產業

• 主要成長指標
• 預測假設與考察- 生物相似藥市場
• 收益預測 - 生物相似藥全球市場
• 收益預測分析—全球生物相似藥市場
• 按產品類型分類的收益預測
• 按產品類型分類的收益和預測分析
• 按治療領域分類的收益預測
• 主要新型和即將推出的生技藥品的專利到期
• 收益預測分析-腫瘤領域
• 收益預測分析 - 肌肉骨骼和免疫學
• 收益預測分析 - 內分泌及眼科
• 競爭環境
• 收益佔有率
• 收益佔有率分析

成長機會宇宙

• 成長機會 1：RWE 解決方案
• 成長機會2：神經生物相似藥
• 成長機會三：聚焦中東與非洲
• 成長機會 4：人工智慧、PD 和組別生物標記的利用
• 成長機會 5：mAb 生物相似藥的替代配方方法

下一步

Increasing Access, Adoption, and Awareness are the Key to Future Growth Potential of Biosimilars

Biosimilar acceptance and use are increasing as patients and healthcare providers improve their understanding and awareness of therapeutic agents driven by biosimilar manufacturers and regulators. As the availability of information and practical data supporting the safety and effectiveness of biosimilars increases, both patients and healthcare professionals are developing a greater level of confidence in these medications. It is imperative for pharmaceutical companies to delicately navigate the intricate balance between safeguarding their biologic products and cultivating an environment conducive to the presence of biosimilars, which inevitably contribute to a thriving competitive milieu.

This study presents overall market and segment-wise revenue forecasts for the global biosimilars market. It highlights key growth opportunities for biosimilar market participants based on the trends, evolution of business models, and strategic imperatives for various stakeholders. It identifies the greatest revenue-generating therapeutic areas and product types. The elements affecting regional biosimilar uptake and biosimilar market entrance have been clearly stated. In addition, this report covers complicated factors, including reimbursement and payer landscape, biosimilar price trends, and biosimilar sales trends that will affect biosimilar penetration. The study discusses regional biosimilar discrepancies as well as industry issues, including physician adoption and patent litigations. This report identifies key growth opportunities to increase biosimilar uptake and innovations and compete for newer therapy areas, such as neurology and oncology.

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Global Biosimilars Market
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Scope of Analysis
• Market Segmentation
• Key Regional Competitors in the Biosimilars Market
• Growth Drivers
• Growth Restraints

Growth Environment-Biosimilars Market

• Highlights-Biosimilars Regional Dynamics
• Growth Opportunities-Biosimilars Market
• Strategies to Boost Biosimilars Development and Adoption
• Biopharma Taking Lead to Boost Adoption of Biosimilars-Sandoz
• North America Competitive Benchmarking-Key Countries
• Market Snapshot-US Biosimilar Market
• Biosimilars Approved in the US
• The US Healthcare Financial and Distribution Pathways
• Business Model Transformation due to the Next Wave of Biosimilars
• Evolving Roles of PBM Formularies to Boost Biosimilar Accessibility
• Evolving US Biosimilar Regulatory Landscape
• US Insulin Biosimilar Market Set for Major Reset in Response to IRA
• Dual Pricing Strategy in the US
• US Oncology
• US Oncology Supportive Care
• US Immunology and Ophthalmology
• Europe Competitive Benchmarking-Key Countries
• Market Snapshot-Europe Biosimilars Market
• Biosimilars Approved in Europe
• Swift and Rapid Adoption of Biosimilar-Denmark Success Story
• Incentives Driving Adoption of Biosimilars
• APAC and MEA Competitive Benchmarking-Key Countries
• Market Snapshot-Key APAC and MEA Biosimilar Market
• Intensifying Focus of Asian Biopharma and CDMO on the Global Market

Growth Opportunity Analysis-Biosimilars Industry

• Key Growth Metrics
• Forecast Assumptions and Considerations-Biosimilars Market
• Revenue Forecast-Global Biosimilars Market
• Revenue Forecast Analysis-Global Biosimilars Market
• Revenue Forecast by Product Type
• Revenue Forecast Analysis by Product Type
• Revenue Forecast by Therapeutic Area
• New and Upcoming Key Biologics Patent Expiration
• Revenue Forecast Analysis-Oncology
• Revenue Forecast Analysis-Musculoskeletal and Immunology
• Revenue Forecast Analysis-Endocrinology and Ophthalmology
• Competitive Environment
• Revenue share
• Revenue Share Analysis

Growth Opportunity Universe

• Growth Opportunity 1: RWE Solutions
• Growth Opportunity 2: Neurology Biosimilars
• Growth Opportunity 3: Focus on the Middle East and Africa
• Growth Opportunity 4: Leveraging AI, PD, and Omics Biomarkers
• Growth Opportunity 5: Alternative Formulation Methodology for mAb Biosimilars

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• List of Exhibits
• Legal Disclaimer